> Shares in one of Neil Woodford’s funds fell 10% after Prothena reported the failure of a phase 2b trial. Woodford bet big on Prothena but, as with some of his previous investments including Circassia, has been stung. A statement by Woodford about the Prothena data was flooded with comments from investors questioning his approach. Statement
> Sofinnova Partners led a €26.5 million ($32.3 million) investment in EryDel. The Italian biotech will use the money to fund a phase 3 trial of its red-blood-cell-based drug delivery system. Release
> Redx Pharma named Lisa Anson as its CEO. Anson, the former president of AstraZeneca in the U.K., arrives at Redx as it seeks to bounce back from financial troubles. Statement
> Autolus licensed a clinical-stage CD19 CAR-T therapy. The candidate is designed to improve on first-generation CD19 CAR-Ts by reducing side effects related to cytokine release syndrome. Release
> Boehringer Ingelheim entered into an antigen-specific tolerance induction collaboration with Topas Therapeutics. The agreement gives Boehringer an option to license preclinical candidates discovered in the collaboration. Statement